Follow
Drug Design
Drug Design: often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target.
-
NOV 20, 2013 | 9:00 AM
The development of CDx assays minimally requires a partnership between a pharmaceutical and a diagnostic company. It is not uncommon for the drug to be developed through an alliance of two ph...Speaker: George A. Green IV, PhDOCT 17, 2013 | 11:00 AMC.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...Speaker: George Poste, DVM, DSc, PhDOCT 16, 2013 | 11:00 AMC.E. CREDITS
Cancer and diabetes are complex diseases that have proven difficult to treat in the clinics. Until recently, most efforts have focused on hitting individual therapeutic targets cleanly. Unfor...Speaker: Ross L. Cagan, PhDOCT 16, 2013 | 11:00 AM
"SuperSelective" primers, by virtue of their unique design, enable only a few molecules of a mutant sequence to generate amplicons in conventional, real-time PCR assays without interference...Speaker: Fred Kramer, PhDOCT 16, 2013 | 11:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, a...Speaker: Michael J Mann, MDOCT 16, 2013 | 10:00 AMC.E. CREDITS
The current paradigm of detecting established cancer (often too late) and treating routinely with cytotoxic drugs is beginning to change. Advanced technologies such as whole genome sequencin...Speaker: Anna Barker, PhDOCT 16, 2013 | 7:00 AMC.E. CREDITS
The adjuvant therapy of choice for superficial bladder cancer is the intravesical instillation of live Mycobacterium bovis Bacillus Calmette-Guerin (BCG). In spite of the fact that this thera...Speaker: R. Claudio Aguilar, PhD
AUG 22, 2013 | 9:00 AM
C.E. CREDITS
There has been considerable debate in the scientific and clinical communities regarding the return of results from genome sequencing to physicians and patients. Questions surrounding which he...
AUG 21, 2013 | 2:00 PM
Increasingly genome sequence knowledge is unraveling the complexity of rare Mendelian disorders offering hope for our children's medical care through better disease diagnosis and ultimately p...
MAY 30, 2013 | 12:00 PM
Development of a companion diagnostic can be critical to the success of a drug. Pharmaceutical companies are committing more and more of their efforts to discover and deliver targeted therapi...
MAY 30, 2013 | 9:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
SEP 13, 2012 | 12:00 PM
C.E. CREDITS
 Direct-to-Consumer (DTC) genome-wide disease risk profiling is currently available to individuals and provides information about one's genetic risk for a range of common polygenic diseases. ...
OCT 26, 2011 | 2:00 PM
 Autophagy is a normal degradative pathway that involves the sequestration of entire organelles, protein complexes, and misfolded proteins in a membrane vacuole called the autophagosome. The ...
NOV 20, 2013 | 9:00 AM
The development of CDx assays minimally requires a partnership between a pharmaceutical and a diagnostic company. It is not uncommon for the drug to be developed through an alliance of two ph...
Speaker:
George A. Green IV, PhD
OCT 17, 2013 | 11:00 AM
C.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
Speaker:
George Poste, DVM, DSc, PhD
OCT 16, 2013 | 11:00 AM
C.E. CREDITS
Cancer and diabetes are complex diseases that have proven difficult to treat in the clinics. Until recently, most efforts have focused on hitting individual therapeutic targets cleanly. Unfor...
Speaker:
Ross L. Cagan, PhD
OCT 16, 2013 | 11:00 AM
"SuperSelective" primers, by virtue of their unique design, enable only a few molecules of a mutant sequence to generate amplicons in conventional, real-time PCR assays without interference...
Speaker:
Fred Kramer, PhD
OCT 16, 2013 | 11:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, a...
Speaker:
Michael J Mann, MD
OCT 16, 2013 | 10:00 AM
C.E. CREDITS
The current paradigm of detecting established cancer (often too late) and treating routinely with cytotoxic drugs is beginning to change. Advanced technologies such as whole genome sequencin...
Speaker:
Anna Barker, PhD
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
The adjuvant therapy of choice for superficial bladder cancer is the intravesical instillation of live Mycobacterium bovis Bacillus Calmette-Guerin (BCG). In spite of the fact that this thera...
Speaker:
R. Claudio Aguilar, PhD
AUG 22, 2013 | 9:00 AM
C.E. CREDITS
There has been considerable debate in the scientific and clinical communities regarding the return of results from genome sequencing to physicians and patients. Questions surrounding which he...
AUG 21, 2013 | 2:00 PM
Increasingly genome sequence knowledge is unraveling the complexity of rare Mendelian disorders offering hope for our children's medical care through better disease diagnosis and ultimately p...
MAY 30, 2013 | 12:00 PM
Development of a companion diagnostic can be critical to the success of a drug. Pharmaceutical companies are committing more and more of their efforts to discover and deliver targeted therapi...
MAY 30, 2013 | 9:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
SEP 13, 2012 | 12:00 PM
C.E. CREDITS
 Direct-to-Consumer (DTC) genome-wide disease risk profiling is currently available to individuals and provides information about one's genetic risk for a range of common polygenic diseases. ...
OCT 26, 2011 | 2:00 PM
 Autophagy is a normal degradative pathway that involves the sequestration of entire organelles, protein complexes, and misfolded proteins in a membrane vacuole called the autophagosome. The ...